Lilly Statement on the National Institute of Allergy and Infectious Diseases Decision to Pause Enrollment in ACTIV-3 Clinical Trial | site |



(October 14, 2020) - - Lilly (the Eli Lilly Company) has published a statement addressing the National Institute of Allergy and Infectious Diseases (NIAID) decision to Pause Enrollment in ACTIV-3 Clinical Trial.

The Lilly statement is located at https://www.lilly.com/news/stories/s...use-enrollment or please press HERE